Physician profile
Jasmine Ryans
NPI 1154000123
$1,762.71
in general payments reported to CMS, 2019-2025
10 companies · $441 in 2025
The $441 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $186 · 2024: $1,135 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,762.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $601.20 | 2023-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $482.19 | 2024-2025 | Airsupra, Breztri |
| Amgen INC. | $301.09 | 2024-2025 | Repatha, Otezla, Repatha |
| Gilead Sciences, INC. | $121.86 | 2025 | Yeztugo |
| Glaxosmithkline, LLC. | $119.81 | 2024 | Arexvy |
| Voco America INC. | $42.54 | 2023 | Voco Profluorid Varnish, Profluorid L |
| Lilly USA, LLC | $32.83 | 2024 | Mounjaro, Zepbound |
| Viiv Healthcare Company | $26.01 | 2025 | Apretude |
| Averitas Pharma INC. | $21.36 | 2025 | Qutenza |
| Exact Sciences Corporation | $13.82 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Ryans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.